U.S. Markets closed

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
63.48-0.36 (-0.56%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close63.84
Open63.84
Bid63.40 x 900
Ask63.50 x 800
Day's Range62.61 - 64.64
52 Week Range38.95 - 124.16
Volume522,301
Avg. Volume1,239,971
Market Cap4.204B
Beta (5Y Monthly)2.31
PE Ratio (TTM)N/A
EPS (TTM)-11.53
Earnings DateOct 29, 2020 - Nov 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est103.94
  • Why Bluebird Bio's Stock Is Trading Higher Today
    Benzinga

    Why Bluebird Bio's Stock Is Trading Higher Today

    Bluebird Bio (NASDAQ: BLUE) shares are trading higher on Thursday after the company reported second-quarter EPS and sales results up from last year. Wedbush also maintained its Outperform rating on the stock.View more earnings on BLUEBluebird Bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.Bluebird Bio shares were trading up 9.54% at $67.98 on Thursday during the time of publication. The stock has a 52-week high of $126.39 and a 52-week low of $38.95.See more from Benzinga * Rocket Companies Opens For Trading At IPO Price * Roku Reports Q2 Earnings Beat, Adds 3.2M Active Accounts * Why Alterity's Stock Is Trading Lower Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates

    Bluebird (BLUE) delivered earnings and revenue surprises of 81.15% and 95.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress
    Business Wire

    bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress

    bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2020 and shared recent operational progress.